FDA receives award for educational broadcasts on medical device safety
ROCKVILLE, Md. The Food and Drug Administration has won an award for a monthly video series designed to promote safe use of medical products and prevent medication errors, the FDA announced Tuesday.
The series, “FDA Patient Safety News,” won the Cheers Award from the Institute for Safe Medication Practices. The award honors organizations that work to prevent medication errors and adverse drug reactions.
The series is broadcast monthly over several medical satellite television networks to more than 4,500 hospitals and long-term care facilities in the United States. It conveys safety information about drugs, devices and vaccines directly from the FDA to pharmacists, physicians, nurses, risk managers and educators. It also contains reports on recalls, safety alerts and medical errors.
FDA grants orphan drug status to two non-Hodgkin’s lymphoma drugs
AMSTERDAM, Netherlands The Food and Drug Administration has granted orphan drug designations to Kiadis Pharma’s drug Reviroc for two types of non-Hodgkin’s lymphoma, Kiadis announced Monday.
The FDA granted one designation for diffuse large B-cell lymphoma and one for follicular lymphoma. The drug is under development for the elimination of cancer cells from an autologous graft in bone marrow transplants for end-stage blood cancer patients.
“This is an important strategic milestone in the development of Reviroc, and we are very pleased with the orphan drug designations received from the FDA,” Kiadis chief executive officer Manja Bouman said in a statement.
The FDA gives orphan drug designations to drugs developed for treating diseases and conditions affecting fewer than 200,000 people in the United States. The designation allows for accelerated review, tax benefits, exemption from user fees and a seven-year period of market exclusivity in the U.S. after regulatory approval.
FDA approves Boostrix vaccine for use in adults
NEW YORK The Food and Drug Administration has approved a booster vaccine for use in adults, manufacturer GlaxoSmithKline announced Monday.
GSK developed the vaccine, Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed), for use in patients aged 10 to 18 as a protection against tetanus, diphtheria and whooping cough; the FDA’s new approval allows for its use in patients aged 19 to 64 as well.
The new approval follows two clinical trials of 3,000 adult patients.
Sanofi-Aventis makes a similar vaccine, Adacel, for use in patients aged 11 to 64.